Advertisement
Table 5 Comparison of neoadjuvant trials with AC followed by docetaxel with or without S-1
| Trials | Patients | Regimen | pCR | |||||
|---|---|---|---|---|---|---|---|---|
| Tumor | cLN+ | Breast + LN | Breast | |||||
| Stage | >4 cm | (%) | +CIS* | –CIS** | +CIS | –CIS | ||
| This study | T1-4c, N1-3 | 45% | 100% | AC→SD | 22.5% | NA | 30.6% | 22.5% |
| NSAPB B-27 [3] | T1c-3, N0-1 | 45% | 30% | AC | 11.5% | NA | 13.7% | 9.6% |
| 45% | 30% | AC→D | 21.8% | NA | 26.1% | 18.9% | ||
| GEPARDUO [13] | T2-3, N0-2 | 32% | 38% | AD | NA | 7.0% | 11.0% | 7.0% |
| 33% | 42% | AC→D | NA | 14.3% | 22.3% | 15.9% | ||
